本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Inhibrx Biosciences

109.27
-2.1500-1.93%
盤後109.270.00000.00%19:30 EDT
成交量:21.10萬
成交額:2,341.92萬
市值:16.03億
市盈率:-12.31
高:115.11
開:113.00
低:108.93
收:111.42
52周最高:155.29
52周最低:26.19
股本:1,467.12萬
流通股本:863.89萬
量比:0.35
換手率:2.44%
股息:- -
股息率:- -
每股收益(TTM):-8.8768
每股收益(LYR):-9.0434
淨資產收益率:-1773.60%
總資產收益率:-43.61%
市淨率:-30.26
市盈率(LYR):-12.08

資料載入中...

2021/03/12

年度報告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2021/02/16

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/02/16

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/02/12

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/02/12

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/02/12

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/02/12

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/02/09

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/01/19

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2021/01/13

重要事件披露

8-K - Current report
2021/01/05

重要事件披露

8-K - Current report
2020/11/13

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2020/11/13

重要事件披露

8-K - Current report
2020/11/12

重要事件披露

8-K - Current report
2020/09/11

重要事件披露

8-K - Current report
2020/08/31

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/08/21

重要事件披露

8-K - Current report
2020/08/19

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2020/08/14

SEC問詢函

CORRESP [Cover] - Correspondence
2020/08/14

SEC問詢函

CORRESP [Cover] - Correspondence